ACA Perspectives: Alkermes Looks For Boon From Expanded Mental Health Benefits
Alkermes’ focus on mental illnesses, substance abuse and other CNS disorders could gain a boost from essential health benefit and mental health parity provisions of the law.
You may also be interested in...
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.